Antibody αPEP13h Reacts With Lymphangioleiomyomatosis Cells in Lung Nodules-Reference-Cited by-同舟云学术

Antibody αPEP13h Reacts With Lymphangioleiomyomatosis Cells in Lung Nodules

Published:2015-03 Issue:3 Volume:147 Page:771-777
ISSN:0012-3692
Container-title:Chest
language:en
Short-container-title:Chest

Author:

Valencia Julio C.,Steagall Wendy K.,Zhang Yi,Fetsch Patricia,Abati Andrea,Tsukada Katsuya,Billings Eric,Hearing Vincent J.,Yu Zu-Xi,Pacheco-Rodriguez Gustavo,Moss Joel

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference43 articles.

1. The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis;Taveira-DaSilva;Lymphat Res Biol,2010

2. NHLBI LAM Registry Group. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment;Ryu;Am J Respir Crit Care Med,2006

3. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement;Glasgow;Chest,2009

4. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis;Carsillo;Proc Natl Acad Sci U S A,2000

5. The tuberous sclerosis complex;Crino;N Engl J Med,2006

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human pluripotent stem cell modeling of tuberous sclerosis complex reveals lineage-specific therapeutic vulnerabilities;2019-06-27

2. Lymphangioleiomyomatosis: a case report and review of diagnosis and treatment;OncoTargets and Therapy;2018-08

3. CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis;Chest;2018-02

4. Addressing the challenges of lymphangioleiomyomatosis assessment in the clinic;Expert Opinion on Orphan Drugs;2017-11-15

5. Epidemiology, pathogenesis and diagnosis of lymphangioleiomyomatosis;Expert Opinion on Orphan Drugs;2016-03-07